Literature DB >> 17290723

Correlation of high sensitivity C-reactive protein and calcific aortic valve disease.

Vinodh Jeevanantham1, Natasha Singh, Kenneth Izuora, John P D'Souza, David H Hsi.   

Abstract

OBJECTIVE: To determine whether a difference exists in the levels of high sensitivity C-reactive protein (Hs-CRP) in patients with and without calcific aortic valve disease (CAVD). PATIENTS AND METHODS: This cross-sectional study consisted of 110 patients who had undergone echocardiographic examination from January 2005 to February 2006 at our institution. Information on demographic variables, coronary risk factors, and medications was obtained. More than 200 patients were excluded on the basis of any evidence of infection, active connective tissue disorder, rheumatoid arthritis, recent episodes of bleeding, acute fractures, bowel obstruction, or acute coronary syndrome or use of corticosteroids, nonsteroidal anti-inflammatory drugs, or antibiotic treatment. The values of Hs-CRP, total cholesterol, and erythrocyte sedimentation rate were included.
RESULTS: Of the 110 study subjects, 38 patients had aortic sclerosis, 36 patients had aortic stenosis, and 36 were controls. The mean Hs-CRP level in the control group was significantly lower (4.84 +/- 6.9 mg/L) compared with the levels in the groups with aortic sclerosis (14.9 +/- 19.6 mg/L) and aortic stenosis (13.6 +/- 17.3 mg/L) (P = -.01). No statistically significant difference was found between the patients in the aortic sclerosis and aortic stenosis groups. Among the patients with aortic stenosis, no significant correlation existed between Hs-CRP levels and aortic stenosis severity.
CONCLUSIONS: The Hs-CRP seems to have a significant association with CAVD during its early stage. The study findings did not have sufficient evidence to suggest the use of Hs-CRP as a marker of progression of calcific aortic stenosis. The Hs-CRP may have a role in identifying patients in the early stages of CAVD and in whom medical treatment may be beneficial to halt the progression to irreversible aortic valvular calcification and stenosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17290723     DOI: 10.4065/82.2.171

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  11 in total

1.  Risk factors for progression of calcific aortic stenosis and potential therapeutic targets.

Authors:  Ashvin R Kamath; Ramdas G Pai
Journal:  Int J Angiol       Date:  2008

2.  C-reactive protein and subclinical cardiovascular disease among African-Americans: (the Jackson Heart Study).

Authors:  Jung Hye Sung; Jae Eun Lee; Tandaw E Samdarshi; Harsha S Nagarajarao; Jason K Taylor; Khushboo K Agrawal; Herman A Taylor; Ervin R Fox
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2014-05       Impact factor: 2.160

3.  Validation of plasma biomarkers in degenerative calcific aortic stenosis.

Authors:  Giovanni Ferrari; Rachana Sainger; Erik Beckmann; Gianluca Keller; Pey-Jen Yu; Maria Cristina Monti; Aubrey C Galloway; Richard L Weiss; William Vernick; Juan B Grau
Journal:  J Surg Res       Date:  2010-05-06       Impact factor: 2.192

4.  Impact of periodontal disease on outcomes in diabetes.

Authors:  Kenneth Izuora; Echezona Ezeanolue; Karen Schlauch; Michael Neubauer; Civon Gewelber; Guillermo Umpierrez
Journal:  Contemp Clin Trials       Date:  2015-01-24       Impact factor: 2.226

5.  Changes in Inflammatory and Bone Turnover Markers After Periodontal Disease Treatment in Patients With Diabetes.

Authors:  Kenneth E Izuora; Echezona E Ezeanolue; Michael F Neubauer; Civon L Gewelber; Gayle L Allenback; Guogen Shan; Guillermo E Umpierrez
Journal:  Am J Med Sci       Date:  2016-04-23       Impact factor: 2.378

Review 6.  Insights into the use of biomarkers in calcific aortic valve disease.

Authors:  Erik Beckmann; Juan B Grau; Rachana Sainger; Paolo Poggio; Giovanni Ferrari
Journal:  J Heart Valve Dis       Date:  2010-07

7.  Association of aortic valve calcification to the presence, extent, and composition of coronary artery plaque burden: from the Rule Out Myocardial Infarction using Computer Assisted Tomography (ROMICAT) trial.

Authors:  Amir A Mahabadi; Fabian Bamberg; Michael Toepker; Christopher L Schlett; Ian S Rogers; John T Nagurney; Thomas J Brady; Udo Hoffmann; Quynh A Truong
Journal:  Am Heart J       Date:  2009-10       Impact factor: 4.749

8.  Linking soluble vascular adhesion molecule-1 level to calcific aortic stenosis in patients with coronary artery disease.

Authors:  Katerina Linhartova; Gabriela Sterbakova; Jaroslav Racek; Roman Cerbak; Karolina Porazikova; Richard Rokyta
Journal:  Exp Clin Cardiol       Date:  2009

Review 9.  Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2010-12-09       Impact factor: 4.162

Review 10.  Role of oxidative stress in calcific aortic valve disease and its therapeutic implications.

Authors:  Harry Z E Greenberg; Guoan Zhao; Ajay M Shah; Min Zhang
Journal:  Cardiovasc Res       Date:  2022-05-06       Impact factor: 13.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.